Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Overtakes GSK to Become Top Indian Pharma Company (India)

This article was originally published in PharmAsia News

Executive Summary

So far in 2007, Cipla has emerged ahead of its competitors to become the top pharmaceutical company in the Indian domestic market with a share of 5.17 percent. Its closest competition is GlaxoSmithKline at 4.89 percent. Local leaders Ranbaxy, Nicholas Piramal, and Zydus Cadila followed up in the third, fourth, and fifth positions respectively. When international sales were taken into account, it was Ranbaxy that came out on top with the highest overall revenues of any Indian pharmaceutical manufacturer. Ranbaxy took the spot from Dr. Reddy's Laboratories, which held the lead position up until two months ago. (Click here for more

You may also be interested in...



GSK Takes Lupin To Court To Block Generic Combivir Launch in the U.S.

MUMBAI - Europe's largest drugmaker GlaxoSmithKline has sued Indian drug maker Lupin for infringement of its patents for anti-AIDS drug Combivir in the U.S

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel